What the procedure actually involves

ChondroFiller — also marketed as Liquid Cartilage — is an injectable collagen scaffold placed directly into the hip joint under real-time ultrasound guidance. The entire procedure takes place in an outpatient clinic setting: there is no theatre booking, no general anaesthetic, and no overnight admission.

On the day, the joint area is prepared under local anaesthesia or mild sedation. Using ultrasound to track the needle in real time, the clinician introduces the scaffold into the target area of the hip. Once inside the joint, the collagen material gels in situ, adapting to the joint environment without requiring any surgical preparation of the cartilage surface beforehand. The session is typically completed in a single appointment.

ChondroFiller is CE-marked as a Class III medical device — the highest regulatory category for implantable and injectable devices in Europe — which provides a formal clinical-safety reference point distinct from cosmetic or nutritional injectables.

Patients can generally expect intravenous antibiotic cover during the procedure and a follow-up review at around six weeks. Guide costs vary by provider and should be confirmed directly at consultation.

Why the hip demands image guidance

The hip sits deep within the pelvis, cushioned by some of the largest muscle groups in the body. Unlike the knee — where the joint line lies close beneath the skin — the hip joint space is separated from the surface by several centimetres of dense soft tissue. That depth makes accurate needle placement genuinely difficult without visual assistance: a clinician relying on anatomical landmarks alone cannot see where the needle tip has arrived or confirm that the injectate has entered the joint rather than the surrounding tissue.

Orthobiologics literature puts the consequences of that uncertainty in concrete terms: in anatomically complex sites, up to 30% of injections placed without image guidance may miss the intended intra-articular target entirely. For a viscous scaffold material such as ChondroFiller, a misplaced deposit cannot fulfil its intended function — the collagen has no mechanism to migrate to the correct location after the fact.

Ultrasound resolves this by providing a real-time picture of the needle tip and the spreading injectate as the clinician works, without exposing the patient to ionising radiation. Fluoroscopy is a recognised alternative guidance method and is used in some settings, but it delivers radiation dose and offers notably weaker soft-tissue contrast than ultrasound — making real-time needle tracking less precise for a deep structure surrounded by muscle rather than bone.

How the scaffold works once it is in place

The scaffold's job begins once the collagen material has settled against the cartilage surface. ChondroFiller contains no donor cells of any kind — 'acellular' simply means the product itself carries no biological material. What it provides instead is a three-dimensional matrix: a structure that progenitor cells from the patient's own synovium and surrounding joint tissue can migrate into, anchor to, and use as a biological template.

Over the weeks and months that follow, those recruited cells begin to differentiate toward cartilage-like tissue within the scaffold. The clinical term for this process is acellular matrix-induced chondrogenesis — the scaffold induces repair by providing architecture; the patient's own biology does the restorative work. This is meaningfully different from cell therapy approaches, in which donor or laboratory-cultured cells are introduced alongside a carrier. It is also distinct from hyaluronic acid (HA) viscosupplementation, which lubricates the joint environment but provides no structural matrix for tissue repair.

In the hip, the scaffold functions as an additional viscoelastic layer laid over degenerated articular surfaces. Because the injection pathway does not require prior debridement of the cartilage bed, nothing is removed before the collagen is introduced. The overall effect is one that supports the body's own repair processes rather than attempting to substitute mechanically for tissue that has been cleared away.

What the evidence shows — and where it is strongest

Across multiple published knee cohort studies, IKDC scores improve by approximately 30 points at 12 months — roughly double the Minimal Clinically Important Difference of 16.7 points, which represents the threshold at which patients notice a meaningful change in function. The Jerosch et al. prospective PMCF study confirmed that this gain holds: participants reached a mean IKDC score of 80.1 at three-year follow-up, with a mean improvement of 32.4 points from baseline. Structural repair matches the functional picture — MOCART MRI scores of 81.6 to 84.3 across European cohorts indicate that more than 80% of defect volume fills with repair tissue over time.

The safety record compares favourably against established alternatives. The complication rate with ChondroFiller approaches zero per cent, against a rate of up to 17% for ACI and MACI; reoperation rates of 3–8% compare with up to 41% for microfracture.

Hip-specific cohort data are at an early stage. Clinic materials reference modified Harris Hip Score improvements of approximately 30 points — broadly consistent with the functional gains seen in knee series — but peer-reviewed hip cohort studies are not yet widely available in the literature. The hip application is best understood as an evidence-supported extension of a knee-validated intervention: the scaffold mechanism is identical, and ultrasound guidance provides the same real-time precision regardless of joint. Patients considering ChondroFiller for the hip should ask their assessing clinician what hip-outcome data are available at the point of referral, and factor the relative maturity of that evidence into their decision.

Which patients are typically assessed

Most patients assessed for ChondroFiller injection share a recognisable clinical profile: a defined area of cartilage damage in the hip — Grade III or IV on arthroscopic grading — where the surrounding joint remains structurally intact enough to benefit from a regenerative scaffold. Equally suitable are patients with early-to-moderate hip osteoarthritis (Kellgren-Lawrence Grade III or IV) who are not yet at the point where joint replacement is being actively discussed.

The underlying cause of damage varies. Femoroacetabular impingement (FAI) — where an abnormal bone shape generates friction at the hip joint — is one of the more common referral triggers, particularly in younger and more active patients. Sports trauma, repetitive loading from occupational or training demands, and age-related degenerative thinning also feature regularly.

In terms of treatment history, typical referrals are patients who have worked through physiotherapy and possibly an earlier injection without lasting relief. The injection pathway is additive — it is suited to joints where something constructive can still be achieved, rather than joints requiring structural replacement.

Where hip cartilage loss is end-stage and total hip replacement is clinically indicated, this pathway is not a substitute. A specialist assessment — usually incorporating imaging to grade defect extent and joint space — distinguishes those two groups. For ChondroFiller specifically, that assessment also determines whether the defect geometry is suitable for scaffold integration, which is what separates a candidate from someone better served by a different intervention.

Finding a specialist who offers this treatment

Knowing the evidence landscape matters when choosing a specialist. Because hip-specific outcome data for ChondroFiller are still maturing relative to the knee literature, the quality of a clinician's own hip caseload becomes part of the decision. When booking a consultation, it is reasonable to ask how many ultrasound-guided hip injections using ChondroFiller the clinician has performed, and whether they can share their own follow-up data alongside the published knee cohort evidence.

ChondroFiller injection for hip cartilage defects is now offered by a growing number of MSK specialists across the UK. Search MSK lists practitioners who provide this treatment — searchable by region and joint — so patients can identify a clinician whose experience and location suit their situation. That consultation is where imaging findings, defect geometry, treatment history, and realistic outcome expectations can be assessed for the individual joint in front of the clinician — the ground on which a genuinely informed decision is made.